SCHD's Top Sector Bet Is Healthcare at 20.7%. I'm Not Sure What's More Surprising: What It Doesn't Hold, or What It Does.

SCHD's healthcare allocation is its largest sector exposure at 20.7%, led by Merck at 4.1% of assets and UnitedHealth at 3.9%, despite excluding dividend stalwarts Johnson & Johnson and Medtronic. Merck faces a major patent-cliff risk as Keytruda, which generated $8.4B of $16.6B in Q2 sales, could lose U.S. exclusivity in 2028, while UnitedHealth continues to face Medicare Advantage, cost, growth, and policy-related pressures. The article views SCHD's annual quality-screening and reconstitution process as a mitigating factor should either holding deteriorate.

Analysis

The relevant exposure is not SCHD’s dividend continuity but its factor concentration: a rules-based “quality dividend” vehicle has accumulated meaningful exposure to two idiosyncratic healthcare risks that are unlikely to be diversified by broad sector beta. MRK’s earnings multiple will increasingly be governed by confidence in replacement revenue versus its 2028 loss-of-exclusivity curve; UNH’s valuation is more sensitive to medical-cost trend, Medicare Advantage reimbursement, and regulatory headlines than to its current yield. A healthcare-weighted dividend ETF can therefore underperform defensives precisely when investors expect stable income exposure.

JNJ and MDT are plausible substitutes for investors seeking lower event-risk healthcare income. JNJ’s diversified earnings base and balance-sheet flexibility should command a relative premium if drug-pricing or managed-care scrutiny intensifies, while MDT offers a multi-year margin-recovery and procedure-volume path less correlated with payer utilization volatility. Conversely, ABT and AMGN retain product-cycle risks, and BMY remains more appropriate as a high-yield value exposure than a clean quality substitute.

Near term, there is no standalone ETF trade catalyst: annual index reconstitution is too slow to protect against an adverse UNH utilization update or MRK pipeline disappointment. Over 1-3 months, watch UNH’s medical-care ratio/2026 cost commentary and MRK’s late-stage trial, business-development, and guidance cadence. Over 6-18 months, sustained relative underperformance of the two largest healthcare exposures could create ETF-level flows and force discretionary holders to rotate toward JNJ/MDT before index changes occur.

Contrarian view: the apparent omission of JNJ and MDT is not necessarily a screen failure; lower yield or trailing growth metrics can mechanically exclude otherwise high-quality franchises. The market may already price MRK’s patent cliff and UNH’s policy risk, so a rotation should be sized as relative-risk management rather than a directional call unless upcoming earnings revise cash-flow expectations materially.

Key Decisions for Investors

• Initiate a 6-12 month defensive healthcare pair: long JNJ and MDT equally, short MRK and UNH equally. Target 8-12% relative return if UNH cost trends remain elevated and MRK’s replacement-revenue visibility fails to improve; exit if UNH restores a credible medical-cost outlook and MRK raises medium-term revenue/earnings guidance.
• For SCHD holders, reduce unintended managed-care and single-asset patent-cliff exposure by complementing, rather than necessarily selling, with JNJ/MDT. Reassess after the next UNH earnings release and after MRK provides updated pipeline or capital-allocation guidance.
• Do not short SCHD on this information alone: its healthcare concentration is meaningful but the proposed risks are company-specific and the annual methodology can eventually rotate exposure. Set an alert if MRK and UNH combined weight rises further at reconstitution or if healthcare exceeds roughly one-quarter of fund assets.
• Use UNH earnings as the near-term catalyst checkpoint: a renewed adverse utilization or reimbursement revision supports the long JNJ/MDT versus short UNH leg; a clean cost-trend normalization is the principal falsifier and warrants covering the UNH short promptly.